Cargando…

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash

Tepotinib is one of the key drugs for MET exon 14-skipping mutation-positive non-small cell lung cancer (NSCLC). The main adverse event of tepotinib treatment is edema. Rash is a rare adverse event, affecting only 0.7% of patients. We report a case of successful desensitization after skin rash cause...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Tomoki, Hata, Sakura, Baba, Takahiro, Koyanagi, Taisaku, Umeno, Takahiro, Nishii, Kazuya, Kuyama, Shoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495622/ https://www.ncbi.nlm.nih.gov/pubmed/37706029 http://dx.doi.org/10.1016/j.rmcr.2023.101911

Ejemplares similares

A case of synovitis-acne-pustulosis-hyperostosis-osteitis syndrome with right pleural effusion
por: Kakimoto, Takayuki, et al.
Publicado: (2023)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

Pseudo-acute kidney injury secondary to tepotinib
por: Wijtvliet, Veerle, et al.
Publicado: (2022)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
por: Grädler, Ulrich, et al.
Publicado: (2023)

Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents
por: Zhang, Niu-niu, et al.
Publicado: (2019)

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
por: Pudelko, Linda, et al.
Publicado: (2020)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

A case of immunoglobulin G4-Related disease with pleural effusion, requiring exclusion of tuberculous pleurisy
por: Doita, Susumu, et al.
Publicado: (2022)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report
por: Ninomaru, Taira, et al.
Publicado: (2021)

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study
por: Xiong, Wenyuan, et al.
Publicado: (2022)

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
por: Albers, Joachim, et al.
Publicado: (2023)

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
por: Makimoto, Go, et al.
Publicado: (2020)

Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
por: Xiong, Wenyuan, et al.
Publicado: (2022)

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates
por: Yalkinoglu, Özkan, et al.
Publicado: (2023)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

Design, Synthesis and Antitumor Activity of Novel Selenium-Containing Tepotinib Derivatives as Dual Inhibitors of c-Met and TrxR
por: Hu, Jinhui, et al.
Publicado: (2023)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
por: Makimoto, Go, et al.
Publicado: (2022)

Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation
por: Abdelhameed, Ali S., et al.
Publicado: (2020)

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
por: Sakai, Hiroshi, et al.
Publicado: (2021)

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
por: Xiong, Wenyuan, et al.
Publicado: (2021)

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
por: Ryoo, Baek-Yeol, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
por: Paik, Paul K., et al.
Publicado: (2022)

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
por: Le, Xiuning, et al.
Publicado: (2023)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
por: Vagiannis, Dimitrios, et al.
Publicado: (2021)

Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways
por: Jing, Guifang, et al.
Publicado: (2022)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
por: Le, Xiuning, et al.
Publicado: (2022)

Drug rash induced by levothyroxine and oral desensitization
por: Dortas, Sérgio Duarte, et al.
Publicado: (2015)

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
por: Makimoto, Go, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2phoitdgi2dlpbqdmgnjmnstdi